<DOC>
	<DOCNO>NCT00666081</DOCNO>
	<brief_summary>This two-part study subject hematologic malignancy design find maximum tolerate dose ( MTD ) GSK690693 ( Part 1 ) . Part 2 design determine efficacy GSK690693 subset subject hematologic malignancy .</brief_summary>
	<brief_title>Study Investigate AKT Inhibitor GSK690693 Subjects With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<criteria>Histologically cytologicallyconfirmed diagnosis hematologic malignancy relapse refractory standard therapy , AND associate human immunodeficiency virus ( HIV ) infection solid organ transplant . Signed write consent provide . At least 18 year age . A woman eligible enter participate study : Nonchildbearing potential , postmenopausal . A man female partner childbearing potential eligible enter participate study either prior vasectomy agree use adequate contraception ( describe ) study , 3 month last dose study drug . Fasting glucose elevate . Laboratory value within range define protocol Previously diagnose diabetes mellitus ( type 1 2 ) , gestational diabetes . Symptomatic untreated central nervous system ( CNS ) involvement hematologic malignancy ( include primary CNS lymphoma ) . Subjects previously treat CNS involvement , asymptomatic without antiepileptic medication steroid least 2 month eligible . Subjects undergone allogeneic stem cell transplant . Unresolved toxicity previous anticancer therapy agree Medical Monitor Investigator , . Major surgery within past 28 day . Chemotherapy , radiotherapy , immunotherapy , investigational drug therapy within 21 day ( 42 day prior nitrosoureas mitomycin C ) prior first dose study medication . For subject acute leukemia , anticancer chemotherapy ( include corticosteroid ) may administer 7 day prior first dose study medication . Chemotherapy give dose schedule expect delayed toxicity give interval 14 day first dose . Hydroxyurea may administer 7 day prior first dose study medication . Current use oral corticosteroid , exception inhale topical corticosteroid . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal disease ) . Any female pregnant lactating . Any serious unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject safety obtain informed consent . Significant ECG abnormality . Use medication know prolong QTc interval within 14 day ( 5 halflives ) prior first dose study medication . History myocardial infarction , acute coronary syndrome , unstable angina coronary angioplasty/stenting/bypass graft within past 6 month . Left ventricular ejection fraction ( LVEF ) less 50 % echocardiogram ( ECHO ) multiple gated acquisition ( MUGA ) scanning . Use theophylline within 14 day first dose study medication . Current use warfarin â‰¥4 mg per day ; however , low molecular weight heparin prophylactic lowdose warfarin permit , PT/PTT &lt; 1.2 x ULN . Concurrent condition Investigator 's opinion would jeopardize subject 's ability comply protocol . History allergic reaction attribute compound similar chemical composition GSK690693 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pazopanib , paclitaxel , carboplatin</keyword>
</DOC>